On March 21 2023 I have been speaking at the World EPA congress in Amsterdam RAI about the use of technology to collect data that makes sense for HTA.
And just as many other speakers have noted during this 3 day event: as the effectuation of The EU regulation on health technology assessment (HTAR) is approaching, there are still many open questions for health technology developers as to how the joint HTA procedures, will bring the desperately needed efficiency and speeding up of reimbursement decisions.
As the joined HTA involves only a joint clinical evaluation at its best, health technology developers may still be confronted with significant duplications of submissions and administrative burden.
The increasing number of new health technologies that promise better outcomes through highly personalized treatment options, can not be assessed as standalone products. Also considering that smaller patients samples are involved, it implies that new methodologies and instruments to measure the effectiveness of the health technology are needed.
While digital & information technology can be of tremendous value to collect data in a highly efficient way, it can only be meaningful in creating robust and high integrity information if HTA stakeholders agree on how to collaborate on finding practical solutions to solve methodological issues.